CUPERTINO, Calif. - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has announced the FDA’s acceptance of its Phase 3 RECOVER-2 study for brilaroxazine, a treatment for schizophrenia. This development marks a significant step in the drug’s path towards a potential New Drug Application (NDA) submission.
3 Likes
This is a potent med with good side effect profile. Seems to be taking forever with approval estimated in 2026.
2 Likes